‘I Really Could Not Refuse’: Pharmascience CEO Arès Reflects On First Six Months
Canadian Generics Manufacturer Has Ambitions To Double Sales By End Of Decade
Executive Summary
Taking over from the son of the company’s founder at the beginning of 2023, Martin Arès, the CEO of Canadian generics manufacturer Pharmascience, talks to Generics Bulletin about investment, international expansion and biosimilars.
You may also be interested in...
Fresenius And Aurobindo Among Fresh Velcade Challengers In US
Multiple firms have launched bortezomib products for subcutaneous administration in the US, adding to competition on Takeda’s Velcade brand.
The Separation Of Sandoz, A Story Years In The Making
Novartis’ shareholders last month voted yes on the proposal to separate Sandoz into a standalone generics and biosimilars firm. On the eve of the spin-off, Generics Bulletin looks back at a deal that was seemingly destined to happen sooner rather than later.
What’s Next? Five Things To Look Out For In October
Generics Bulletin previews the most notable and anticipated events for October 2023.